Air Industries Group — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. The unaudited consolidated results cover AIRI and its wholly owned subsidiaries. The company began reporting as one operating segment in Q1 2022, following integration of its machining and turbine/engine operations.
Financial performance and position
- Q2 revenue: $14.008 million, down 9.4% from $15.453 million a year earlier. Military sales were $11.801 million; commercial sales were $2.207 million.
- Q2 profitability: Gross profit was $2.422 million, with a 17.3% gross margin versus 16.8%. Operating income was $250,000 versus $440,000; net loss was $7,000 versus net income of $239,000.
- First-half revenue: $26.070 million, down 10.6% from $29.165 million. Gross profit rose to $4.500 million from $4.400 million; gross margin improved to 17.3% from 15.1%. Operating income was $457,000 versus $467,000; net loss was $35,000 versus net income of $87,000.
- Cash flow, first half: Operating activities provided $315,000, compared with $181,000 used in 2021. Capital expenditures used $1.327 million; financing provided $1.315 million. Cash increased $303,000 to $930,000.
- Liquidity at June 30: Working capital was $18.902 million and current assets were $43.249 million against current liabilities of $24.347 million. Inventory was $32.988 million.
- Debt: Webster revolver borrowings were approximately $13.344 million and the term loan was $4.879 million; the revolving facility limit is $20 million and the facility matures December 30, 2025. Related-party subordinated notes totaled $6.412 million, due July 1, 2026. AIRI reported compliance with Webster’s financial covenants at quarter-end.
- Other balance-sheet items: Total assets were $55.608 million, total liabilities $37.939 million, and stockholders’ equity $17.669 million. No income tax expense was recorded; deferred tax assets remain fully reserved.
Changes from the prior comparable period
- Sales declined mainly because two products’ contracts expired or were cancelled in 2021; management attributed approximately $115,000 of the Q2 decline and $1.575 million of the first-half decline to those products.
- Q2 gross margin improved modestly despite lower sales, while operating income and net results weakened. For the first half, gross margin improved, but net income turned to a small loss.
- Operating cash flow improved year over year, but inventory growth used $3.456 million of cash in the first half. AIRI also spent $1.327 million on property and equipment, versus $631,000 in the prior-year period.
- In May 2022, AIRI amended its Webster facility, increasing the term loan to $5 million, adding a $2 million equipment line, and adjusting term-loan installments and permitted capital expenditures.
Outlook, risks and notable items
- Management said it expects fiscal 2022 sales to be in line with fiscal 2021 and believes short-term liquidity is adequate and expected to improve. It said higher interest rates may raise borrowing costs but are not expected to materially affect liquidity.
- Backlog at June 30 was approximately $73 million, with expected recognition of $25–$30 million in the remainder of 2022, $25–$30 million in the first half of 2023, and $13–$18 million in the second half of 2023. These estimates depend on timely supplier deliveries and customer acceptance.
- Customer concentration is substantial: three customers accounted for 66.2% of Q2 sales and four accounted for 77.9% of first-half sales. Three customers represented 67.7% of gross receivables at quarter-end.
- Management cited inflation, skilled-labor availability, fixed-price contract economics, and supply-chain disruption—including possible titanium availability effects related to the war in Ukraine—as risks. The company also relies on certain sole-source suppliers and is exposed to defense-budget and aircraft-demand changes.
- AIR Industries faces a disputed Contract Pharmacal claim, reduced to $700,000; the company intends to oppose the claim and is appealing an adverse court ruling. The filing also notes other vendor, landlord, and injury-related claims without clear quantified exposure.
- Backlog revenue depends on delivery and acceptance assumptions. Interim inventory values are estimated using a prior-year gross-profit percentage; actual results may differ from estimates. The company reported no off-balance-sheet arrangements and said disclosure controls were effective.
- After quarter-end, AIRI paid $250,000 on related-party subordinated debt and issued 77,157 shares for directors’ fees.
Key facts for investors to verify
- Whether the $73 million backlog converts on the stated schedule, given supplier, production, and customer-acceptance dependencies.
- Availability under the Webster revolver and equipment line, covenant headroom, and the effect of higher interest rates on cash needs.
- Whether inventory growth and customer concentration create working-capital, delivery, or collection risks.
- The status and potential financial impact of the Contract Pharmacal appeal and other contingencies.
- How results compare on a consistent basis after the change to one reportable operating segment, and how interim inventory estimates affect reported margins.